Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARX vs RYAN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

ARX Overall Winner 6-Pillar Tally: ARX 3 – 3 RYAN Matrix Metrics: ARX 6 – 4 RYAN

As of Nov 16, 2026, Accelerant Holdings (ARX) is the stronger overall head-to-head candidate over Ryan Specialty Holdings, Inc. (RYAN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). ARX carries a Unified Composite Score of 46.9/100 (HOLD) at $19.87 (21.3x Forward P/E, 3.7% operating margin), whereas RYAN carries 40.7/100 (SELL) at $47.86 (19.7x Forward P/E, 19.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARX vs RYAN
ARX NYSE Head-to-Head Winner
Accelerant Holdings
Insurance Agents, Brokers & Service
$19.87
+0.1% 1D
Market Cap $4.3B
TTM Revenue $2.79B
Forward P/E 21.3x
Beta / 30D Vol -0.19β · 2% Vol
Unified Composite Score
46.9 / 100 HOLD
Tech 34.0 Fund 50.0 Flow 76.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.5% over 20 days), RSI 70
RSI-14: 69.8 · SMA20: $19.83 · SMA50: $19.80
RYAN NYSE
Ryan Specialty Holdings, Inc.
Insurance Agents, Brokers & Service
$47.86
+2.07% 1D
Market Cap $11.9B
TTM Revenue $6.20B
Forward P/E 19.7x
Beta / 30D Vol -0.32β · 39% Vol
Unified Composite Score
40.7 / 100 SELL
Tech 22.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.6% over 20 days), RSI 67
RSI-14: 66.9 · SMA20: $45.34 · SMA50: $41.30

6-Pillar Scorecard Institutional Category Breakdown (ARX 3 – 3 RYAN)

Columns: Metric · ARX · RYAN
1. Valuation Multiples RYAN
Forward P/E 21.3x 19.7x
Trailing P/E 27.6x 58.6x
PEG Ratio N/M N/M
EV / Revenue N/M 1.9x
2. Growth & Scale ARX
Revenue Growth (YoY) +6.1% +4.8%
Earnings Growth (YoY) +800.0% +43.1%
TTM Revenue (USD) $2.79B $6.20B
Market Cap $4.3B $11.9B
3. Profitability & Quality RYAN
Gross Margin 62.8% 41.1%
Operating Margin 3.7% 19.8%
Net Profit Margin 5.6% 3.3%
Return on Equity (ROE) 9.2% 25.1%
4. Balance Sheet & Cash Flow RYAN
Cash Generation (TTM) $634M $1.77B EBITDA
Cash Flow Margin 22.7% 28.5% EBITDA Mgn
Net Cash / Leverage $5.13B Net Cash $3.71 Book/Sh · 25.1% ROE
Dividend Yield None (0.00%) 1.11%
5. Options & Positioning ARX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 15.7% (3rd %ile) 29.7% (12th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ARX
OpEx & R&D Intensity 59.1% of Rev ($1.65B) 21.3% of Rev ($1.32B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Insurance Brokers Operator Insurance Brokers Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARX (6) vs RYAN (4)
Institutional Metric ARX RYAN Criterion Row Edge
Market Capitalization
Scale
$4.3B $11.9B Larger Scale RYAN
Trailing P/E Ratio
Valuation
27.6x 58.6x Lower Multiple ARX
Forward P/E Ratio
Valuation
21.3x 19.7x Lower Multiple RYAN
Revenue Growth (YoY)
Growth
+6.1% +4.8% Higher Growth ARX
Operating Margin (TTM)
Profitability
3.7% 19.8% Higher Margin RYAN
Net Profit Margin
Profitability
5.6% 3.3% Higher Margin ARX
Return on Equity (ROE)
Capital Efficiency
9.2% 25.1% Higher ROE RYAN
52-Week Range Position
Momentum
100% ($9–$20) 63% ($29–$59) Stronger Trend ARX
Beta / 30D Volatility
Risk Regime
-0.19β · 2% Vol -0.32β · 39% Vol Lower Realized Risk ARX
Unified Institutional Score
Composite Signal
46.9 / 100 (HOLD) 40.7 / 100 (SELL) Higher Composite ARX
Trailing 12M Revenue (USD)
Operating Scale
$2.79B $6.20B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
62.8% 41.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$634M ($5.13B Net Cash) $1.77B EBITDA ($3.71 Book/Sh · 25.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RYAN +16.84 pp
ARX: +0.61% · RYAN: +17.45%
3M Horizon RYAN +14.47 pp
ARX: +1.58% · RYAN: +16.05%
6M Horizon RYAN +17.25 pp
ARX: +24.89% · RYAN: +42.14%
1Y Horizon ARX +60.23 pp
ARX: +44.4% · RYAN: -15.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARX vs RYAN. Trailing 12-month operating profitability (ARX 3.7% vs RYAN 19.8%) and valuation multiples (ARX 21.3x vs RYAN 19.7x Forward P/E) are benchmarked directly in Pillar 4 below.

ARX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.79B
Gross Margin62.8%
Op. Margin3.7%
ROE / Fwd P/E9.2% · 21.3x
RYAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.20B
Gross Margin41.1%
Op. Margin19.8%
ROE / Fwd P/E25.1% · 19.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARX CONSOLIDATION
50d in phase · OBV NEUTRAL
Current IV 15.7%
IV Percentile 3rd %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ARX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RYAN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 29.7%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RYAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARX Moat Profile Cyclical / Execution-Driven Positioning
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $4.3B market capitalization and 3.7% operating margin.
OpEx & R&D Reinvestment 59.1% of Rev ($1.65B)
90D Engineering Disclosures 0 Published
RYAN Moat Profile Scale & Operating Efficiency Moat
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $11.9B market capitalization and 19.8% operating margin.
OpEx & R&D Reinvestment 21.3% of Rev ($1.32B)
90D Engineering Disclosures 0 Published

Investor FAQ ARX vs RYAN Key Questions & Quantitative Answers

As of Nov 16, 2026, Accelerant Holdings (ARX) is the stronger overall head-to-head candidate over Ryan Specialty Holdings, Inc. (RYAN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning, R&D & Supply-Chain Moat). ARX carries a Unified Composite Score of 46.9/100 (HOLD) at $19.87 (21.3x Forward P/E, 3.7% operating margin), whereas RYAN carries 40.7/100 (SELL) at $47.86 (19.7x Forward P/E, 19.8% operating margin). Technically, ARX sits in a Markup phase (RSI 69.8, CONSOLIDATION options structure) and RYAN sits in a Markup phase (RSI 66.9, UNCLASSIFIED options structure).

ARX leads the Growth & Scale pillar: ARX posts +6.1% YoY revenue growth and +800.0% YoY earnings growth on $2.79B TTM revenue (62.8% gross margin, 3.7% operating margin), compared with RYAN at +4.8% YoY revenue growth and +43.1% YoY earnings growth on $6.20B TTM revenue (41.1% gross margin, 19.8% operating margin). On trailing 12-month operating scale, ARX generates $2.79B in USD-normalized revenue versus $6.20B for RYAN. In operating R&D and SG&A reinvestment, ARX deploys 59.1% of Rev ($1.65B) (0 90-day corporate R&D disclosures) versus 21.3% of Rev ($1.32B) (0 disclosures) for RYAN.

RYAN screens cheaper on headline valuation multiples. ARX trades at 21.3x Forward P/E, 27.6x Trailing P/E, N/M PEG, and N/M EV/Revenue (22.7% FCF margin), whereas RYAN trades at 19.7x Forward P/E, 58.6x Trailing P/E, N/M PEG, and 1.9x EV/Revenue (28.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARX (9.2% ROE) versus RYAN (25.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ARX carries 15.7% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.19β · 2% Vol realized risk). By comparison, RYAN carries 29.7% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.32β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.